Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KDNY - Chinook Therapeutics Inc


IEX Last Trade
40.325
-0.025   -0.062%

Share volume: 4,669,048
Last Updated: Tue 08 Aug 2023 09:59:47 PM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$40.35
-0.03
-0.06%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
30%
Profitability 25%
Dept financing 20%
Liquidity 40%
Performance 34%
Company vs Stock growth
vs
Performance
5 Days
2.99%
1 Month
3.20%
3 Months
99.16%
6 Months
63.49%
1 Year
97.41%
2 Year
224.88%
Key data
Stock price
$40.32
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$18.34 - $40.47
52 WEEK CHANGE
$0.97
MARKET CAP 
2.705 B
YIELD 
N/A
SHARES OUTSTANDING 
67.049 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,532,626
AVERAGE 30 VOLUME 
$1,856,498
Company detail
CEO: Stephen Isaacs
Region: US
Website: http://www.aduro.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.

Recent news